Abstract:Background: Diffuse large B-cell lymphoma (DLBCL) comprises at least two main biologically distinct entities: germinal center B-cell (GCB) and activated B-cell (ABC) subtype. Albeit sharing common lesions, GCB and ABC DLBCL present subtype-specific oncogenic pathway perturbations. ABC DLBCL is typically characterized by a constitutively active NF-kB. However, the latter is seen in also 30% of GCB DLBCL. Another recurrent lesion in DLBCL is an 11q24.3 gain, associated with the overexpression of two ETS transcription factors, ETS1 and FLI1. Here, we showed that FLI1 is more expressed in GCB than ABC DLBCL and we characterized its transcriptional network. Methods: Gene expression data were obtained from public datasets GSE98588, phs001444.v2.p1, GSE95013 and GSE10846. ChIP-Seq for FLI1 paired with transcriptome analysis (RNA-Seq) after FLI1 silencing (siRNAs) was performed. Sequencing was carried out using the NextSeq 500 (Illumina). Detection of peaks was done using HOMER (v2.6); differential expressed genes were identified using moderated t-test (limma R-package) and functionally annotated with g:Profiler. ChIP-Seq and RNA-Seq data from GCB DLBCL cell lines after FLI1 downregulation were integrated to identify putative direct targets of FLI1. Results: Analysis of clinical DLBCL specimens showed that FLI1 gene was more frequently expressed at higher levels in GCB than in ABC DLBCL and its protein levels were higher in GCB than in ABC DLBCL cell lines. Genes negatively regulated by FLI1 included tumor suppressor genes involved in negative regulation of cell cycle and hypoxia. Among positively regulated targets of FLI1, we found genes annotated for immune response, MYC targets, NF-κB and BCR signaling and NOTCH pathway genes. Of note, direct targets of FLI1 overlapped with genes regulated by ETS1, the other transcription factor gained at the 11q24.3 locus in DLBCL, suggesting a functional convergence within the ETS family. Positive targets of FLI1 included the NF-κB-associated ASB2, a putative essential gene for DLBCL cell survival. ASB2 gene downregulation was toxic in GCB DLBCL cell lines and induced NF-κB inhibition via downregulation of RelB and increased IκBα. Additionally, downregulation of FLI1, but not ASB2, caused reduction of NF-κB1 and RelA protein levels. Conclusions: We conclude that FLI1 directly regulates a network of biologically crucial genes and processes in GCB DLBCL. FLI1 regulates both the classical NF-κB pathway at the transcriptional level, and the alternative NF-κB pathway, via ASB2. FLI1 and ASB2 inhibition represents a potential novel therapeutic approach for GCB DLBCL.

FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B expression

Friend Leukemia Virus Integration 1 is a Predictor of Poor Prognosis of Breast Cancer and Promotes Metastasis and Cancer Stem Cell Properties of Breast Cancer Cells

FLI1 regulates inflammation-associated genes to accelerate leukemogenesis

FLI1 accelerates leukemogenesis through transcriptional regulation of pyruvate kinase-L/R and other glycolytic genes

The ets transcription factor Fli-1 in development, cancer and disease

Continuous Fli-1 Expression Plays an Essential Role in the Proliferation and Survival of F-MuLV-induced Erythroleukemia and Human Erythroleukemia.

FLI1 Expression is Correlated with Breast Cancer Cellular Growth, Migration, and Invasion and Altered Gene Expression

Expression of Fli-1 and the Proliferation and Survival of Small Cell Lung Cancer Cells.

The Inositol Phosphatase SHIP-1 is Negatively Regulated by Fli-1 and Its Loss Accelerates Leukemogenesis

Novel Flavagline-Like Compounds with Potent Fli-1 Inhibitory Activity Suppress Diverse Types of Leukemia

Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogenesis

EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma

FLI-1 is expressed in a wide variety of hematolymphoid neoplasms: a special concern in the differential diagnosis

Transcription factor Fli-1 as a new target for antitumor drug development

An intricate regulatory circuit between FLI1 and GATA1/GATA2/LDB1/ERG dictates erythroid vs. megakaryocytic differentiation

ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma

[Expression of Transcription Factor LYL1 in Leukemia and Its Possible Role in Leukemogenesis].

Friend Leukemia Virus Integration 1 Promotes Tumorigenesis of Small Cell Lung Cancer Cells by Activating the Mir-17-92 Pathway

Retroviral Insertional Activation of the Fli-3 Locus in Erythroleukemias Encoding a Cluster of Micrornas That Convert Epo-induced Differentiation to Proliferation.

UHRF1 plays an oncogenic role in small cell lung cancer

Oncogenic FLT3 internal tandem duplication activates E2F1 to regulate purine metabolism in acute myeloid leukaemia